ISSN 1662-4009 (online)

ey0020.2-12 | New Perspectives | ESPEYB20

2.12. Pappalysins and stanniocalcins and their relationship with the peripheral IGF axis in newborns and during development

A Martin-Rivada , S Guerra-Cantera , A Campillo-Calatayud , EM Andres-Esteban , M Sanchez Holgado , GA Martos-Moreno , J Pozo , M Guemes , L Soriano-Guillen , A Pellicer , C Oxvig , J Frystyk , JA Chowen , V Barrios , J Argente

Brief summary: Growth Hormone (GH)-Insulin-Growth-Factor-1 (IGF-1) axis plays the major role in promoting growth, but novel factors seem to modulate GH-IGF1 axis functioning. The majority of circulating IGF-1 and IGF-2 are bound to IGF-binding proteins (IGF-BPs) which prolong their half-life and regulate their tissue distribution (1,2). Pappalysins (PAPP-A, PAPP-A2) increase IGF-1 bioavailability through cleavage of IGFBPs and are inhibited by stanniocalcins (STC1, STC2) (3,4)...

ey0018.6-14 | Longterm Effects of Hormonal Treatments in Gender Dysphoria | ESPEYB18

6.14. Thrombosis Risk in Transgender Adolescents Receiving Gender-Affirming Hormone Therapy

ES Mullins , R Geer , M Metcalf , J Piccola , A Lane , LAE Conard , TLK Mullins

Pediatrics. 2021 Mar 22:e2020023549. doi: 10.1542/peds.2020-023549. PMID: 33753543.This retrospective, single center chart review study assessed the incidence of arterial or venous thrombosis during gender affirming hormone therapy (GAHT) in 611 transgender adolescents. The prevalence of thrombosis risk factors was also investigated. No increased risk of thrombosis was found over a short ...

ey0021.13-15 | Identifying Health Disparities and Improving Access to Healthcare | ESPEYB21

13.15. The I-CAH registry: a platform for international collaboration for improving knowledge and clinical care in congenital adrenal hyperplasia

X Tseretopoulou , J Bryce , M Chen , M McMillan , AK Lucas-Herald , SR Ali , SF Ahmed

Brief Summary: The authors describe the development and utility of an international collaborative database in congenital adrenal hyperplasia (CAH). I-CAH serves as a tool for benchmarking clinical care and supporting research and development of novel therapies.Rare disease registries can form the basis of best practice guidelines and allow for monitoring of new drugs and therapeutic interventions. The I-CAH Registry was developed as an international plat...

ey0018.10-5 | (1) | ESPEYB18

10.5. Type 1 diabetes mellitus and its oral tolerance therapy

RF Mao , YY Chen , J Zhang , X Chang , YF Wang

World J Diabetes. 2020;11(10):400–415. doi: 10.4239/wjd.v11.i10.400Based on a review of the proposed mechanisms of the development of T1DM, the authors provide an overview of oral tolerance therapies for T1DM conducted in both animal models and clinical trials. This key paper also outlines its future perspectives.As a mainly T cell-mediated autoimmune disease, T...

ey0019.10-3 | Clinical Trials | ESPEYB19

10.3. Randomized trial of closed-loop control in very young children with type 1 diabetes

J Ware , JM Allen , CK Boughton , ME Wilinska , S Hartnell , A Thankamony , Beaufort C de , U Schierloh , E Frohlich-Reiterer , JK Mader , TM Kapellen , B Rami-Merhar , M Tauschmann , K Nagl , SE Hofer , FM Campbell , J Yong , KK Hood , J Lawton , S Roze , J Sibayan , J Bocchino , C Kollman , R Hovorka , Consortium KidsAP

N Engl J Med. 2022 Jan 20;386(3):209-219. https://pubmed.ncbi.nlm.nih.gov/35045227/Brief Summary: This multicenter, randomized, crossover trial in 74 very young children (age: 1-7 years) with type 1 diabetes (T1D) tested the safety and efficacy of a hybrid closed-loop system for insulin delivery (CamAPS FX) compared with sensor-augmented pump therapy over 16 weeks. The hybrid closed-loop sy...

ey0018.3-9 | Congenital hypothyroidism | ESPEYB18

3.9. Newborn screening TSH values less than 15 mIU/L are not associated with long-term hypothyroidism or cognitive impairment

R West , J Hong , JGB Derraik , D Webster , NL Heather , PL Hofman

J Clin Endocrinol Metab. 2020;105:dgaa415. doi: 10.1210/clinem/dgaa415.The optimal cut-off for neonatal screening has long been a matter of debate. The optimal balance between optimal detection of cases and increase of false positive patients is difficult to define. Also, in the most recent guidelines for congenital hypothyroidism (see previous paper in this chapter 3.7), no precise cut-off...

ey0015.5-5 | New genes and gene mutations | ESPEYB15

5.5 Aggrecan Mutations in Nonfamilial Short Stature and Short Stature Without Accelerated Skeletal Maturation

C Tatsi , A Gkourogianni , K Mohnike , D DeArment , S Witchel , AC Andrade , TC Markello , J Baron , O Nilsson , YH Jee

To read the full abstract: J Endocr Soc 2017;1:1006-1011Besides its structural role in the extracellular matrix, aggrecan orchestrates a plethora of key mechanisms in endochondral ossification, such as embryonic morphogen distribution, regular indian hedgehog (IHH) / Sox9 expression and columnar chondrocyte orientation. Thus, homozygous loss-of-function mutations in the ACAN gene, encoding...

ey0018.8-4 | Important for Clinical Practice | ESPEYB18

8.4. Urinary GC-MS steroid metabotyping in treated children with congenital adrenal hyperplasia

C Kamrath , MF Hartmann , J Pons-Kuhnemann , SA Wudy

Metabolism. 2020; 112: 154354.https://pubmed.ncbi.nlm.nih.gov/32916150/In order to better define treatment groups and improve treatment monitoring, the authors performed a retrospective metabotyping analysis using 24-h GC–MS urinary steroid metabolome measurements in young prepubertal children (n=109; age 7.0–1.6 years) with classical congenital adrenal hyperplasia (CAH) ...

ey0020.1-14 | Pediatric Thyroid Cancer | ESPEYB20

1.14. Longitudinal analysis of cancer risk in children and adults with germline PTEN variants

L Yehia , G Plitt , AM Tushar , J Joo , CA Burke , SC Campbell , K Heiden , J Jin , C Macaron , CM Michener , HJ Pederson , K Radhakrishnan , J Shin , J Tamburro , S Patil , C Eng

Brief summary: PTEN hamartoma tumor syndrome is one of five well known genetic syndromes associated with differentiated thyroid carcinoma (1,2). PTEN hamartoma tumor syndrome comprises four different entities: Cowdwn syndrome, Bannayan-Riley-Ruvalcaba syndrome, PTEN-related Proteus syndrome, and Proteus-like syndrome caused by mutations in the PTEN (phosphatase and tensin homologue) tumor suppressor gene [3]. This prospective longitudinal mu...

ey0019.3-12 | Autoimmune Thyroid Disease | ESPEYB19

3.12. The 2022 European Thyroid Association guideline for the management of pediatric Graves' disease

CF Mooij , TD Cheetham , FA Verburg , A Eckstein , SH Pearce , J Leger , ASP van Trotsenburg

Eur Thyroid J. 2022 Jan 1;11(1):e210073. doi: 10.1530/ETJ-21-0073. PMID: 34981748The 2022 European Thyroid Association Guidelines for the management of Graves’ disease in the pediatric age group is an important document summarizing all aspects of the disease, ranging from diagnosis, medical treatment with its advantages and side effects, definitive treatment by thyroidectomy or radioiodine a...